Vanguard Value ETF

Most Recent

  • uploads///cash rich companies
    Company & Industry Overviews

    How Tax Reform Affected Abbott’s 4Q17 Performance

    In 4Q17, Abbott Laboratories (ABT) reported $828 million in net losses, which came in at $0.48 per share.

    By Sarah Collins
  • uploads///EPS ESTIMATES
    Earnings Report

    ZBH’s 4Q17 Earnings Results Meet Analysts’ Estimates

    Zimmer Biomet Holdings announced its 4Q17 and 2017 results on January 30. The company’s sales exceeded analysts’ estimates, while its adjusted earnings per share managed to meet estimates.

    By Sarah Collins
  • uploads///guidance
    Company & Industry Overviews

    A Look at Johnson & Johnson’s 2018 Guidance

    Johnson & Johnson (JNJ) provided 2018 guidance during the company’s earnings results release on January 23, 2018.

    By Sarah Collins
  • uploads///DIABETES
    Company & Industry Overviews

    Developments in J&J’s Medical Device Business Could Drive Growth

    In October 2017, Johnson & Johnson (JNJ) exited its insulin pump business, which was experiencing a decline in sales due to the intense competition in the insulin pump market.

    By Sarah Collins
  • uploads///NASH
    Company & Industry Overviews

    Which Gilead Sciences Portfolio Could Give a Long-Term Boost

    NASH is a chronic disease related to steatosis wherein fat accumulates in the liver and can lead to inflammation, progressive fibrosis, and cirrhosis.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Segment-Wise Performance in 4Q17

    Johnson & Johnson’s (JNJ) Pharmaceuticals segment reported 17.6% growth in revenues to ~$9.7 billion during 4Q17, compared to ~$8.2 billion during 4Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Xeljanz Sees Rapid Adoption in 2017

    Xeljanz demand trends In 3Q17, Pfizer’s (PFE) Xeljanz reported revenue of ~$348 million, marking YoY (year-over-year) growth of ~48.1%. The drug saw sales of $935 million in the first nine months of 2017, a 44.1% YoY rise. In 3Q17, the drug’s new rheumatology prescriptions rose significantly. In September 2017, Xeljanz accounted for 9.8% of new prescriptions for RA (rheumatoid arthritis) in […]

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    First-Line NSCLC Continues to Be a Major Indication for Keytruda

    In May 2017, Keytruda’s chemotherapy combination regimen was approved by the U.S. Food and Drug Administration (or FDA) in a first-line metastatic NSCLC indication.

    By Margaret Patrick
  • uploads///Forteo
    Company & Industry Overviews

    How Eli Lilly’s Forteo and Jardiance Are Performing

    In 3Q17, Eli Lilly’s (LLY) Forteo generated revenues of $441.7 million, ~13% growth on a year-over-year (or YoY) basis and a 1% decline on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads/// Smart beta
    Real Insights

    Can Smart Beta Go Wrong?

    The smart beta approach aims to benefit from market inefficiencies to deliver higher risk-adjusted returns and improve diversification.

    By VanEck
  • uploads///rd milestones
    Company & Industry Overviews

    Inside Baxter’s Recent Developments in Peritoneal Dialysis Care

    Baxter International’s (BAX) PD (peritoneal dialysis) solutions are among the key growth drivers of the company’s renal therapies business.

    By Sarah Collins
  • uploads///Vaccines
    Company & Industry Overviews

    How Are Pfizer’s Vaccines and Biosimilars Positioned after 3Q17?

    In 3Q17, Pfizer’s vaccines business generated revenues of $1.6 billion, which reflected ~1% growth on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///analyst recommendations
    Company & Industry Overviews

    Abbott on the Street: Analyst Recommendations

    Abbott registered strong 3Q17 results, surpassing estimates for both sales and earnings and reporting healthy growth across all of its business segments.

    By Sarah Collins
  • uploads///medical device segment performance
    Company & Industry Overviews

    How JNJ’s Medical Devices Business Restructuring Efforts Are Panning Out

    In 3Q17, Johnson & Johnson (JNJ) reported ~$19.7 billion in sales. The company’s Medical Devices business generated ~33.5% of the total sales.

    By Sarah Collins
  • uploads///HIGHLIGHTS
    Company & Industry Overviews

    Zimmer Biomet’s Knee Sales in 3Q17: What’s Ahead?

    In the quarter ended September 30, 2017, Zimmer Biomet Holdings (ZBH) registered a YoY (year-over-year) fall of 1.5% on a constant currency basis, excluding the impact of the LDR acquisition.

    By Sarah Collins
  • uploads///ALR ABT acquisition
    Company & Industry Overviews

    Abbott-Alere Deal Wins Conditional US Antitrust Approval

    The Federal Trade Commission recently announced the US antitrust approval for Abbott Laboratories’ (ABT) acquisition of Alere (ALR).

    By Sarah Collins
  • uploads///knee market share
    Company & Industry Overviews

    ZBH’s Persona Partial Knee Launch Expands Knee Implant Portfolio

    On September 11, 2017, Zimmer Biomet Holdings (ZBH) announced the launch of its Persona Partial Knee System.

    By Sarah Collins
  • uploads///Vaccine Franchise
    Company & Industry Overviews

    How Merck’s Vaccines Business Is Positioned after 2Q17

    In 2Q17, Merck’s (MRK) Gardasil/Gardasil 9 generated revenues of ~$469 million, which reflected ~19% growth year-over-year and ~12% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///analyst recommendations
    Earnings Report

    JNJ on the Street: The Analyst View after the 2Q17 Results

    Of the 22 brokerage firms covering JNJ, ten (~45%) have rated the stock a “buy,” while 12 (55%) have rated it as a “hold.” None has rated the stock a “sell.”

    By Sarah Collins
  • uploads///Hospital Acute care
    Company & Industry Overviews

    Bridion Could Drive Merck’s Acute Hospital Care Franchise in 2017

    In 2016, Primaxin reported revenues of around $297 million compared to $313 million in 2015.

    By Daniel Collins
  • uploads///MEDICAL DEVICE REVENUES
    Company & Industry Overviews

    How Johnson & Johnson Is Bulking up in Orthopedics Devices

    JNJ reported ~$17.8 billion in revenues in 1Q17, registering a YoY sales growth of around 1.6%. Its Medical Device segment reported ~3% growth.

    By Sarah Collins
  • uploads///confirm ICM
    Company & Industry Overviews

    Technological Advancements Drive Abbott’s New Product Approvals

    On May 8, 2017, Abbott Laboratories (ABT) announced the CE Marking approval of its Confirm Rx ICM. ABT stock rose 0.09% that day.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Baxter’s Renal Business Continues to Be Key Growth Driver

    In 1Q17, Baxter’s (BAX) renal segment reported revenues close to $896.0 million, which is an operational growth of around 2.0% YoY.

    By Margaret Patrick
  • uploads/// Pie
    Real Insights

    Jury Hasn’t Decided on ETFs’ Role in Stock Market Rise

    Although ETF (VTV) ownership increased substantially during the last 20 years, it still isn’t high enough to meaningfully impact stock prices.

    By Peter Barnes
  • uploads///Graph
    Company & Industry Overviews

    Merck: Keytruda Label Continues to Expand in 2017

    Besides lung cancer and melanoma, Merck (MRK) is aggressively expanding Keytruda’s label across multiple cancer indications.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Quest Diagnostics’ Reference Testing, Hospital Outreach Segment

    With services offered to about half of the total hospitals, Quest Diagnostics (DGX) has become a leading provider of reference testing services in the United States.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    UnitedHealth Group Witnessed Robust Customer Growth in 1Q17

    In 1Q17, UnitedHealth Group’s (UNH) UnitedHealthcare business witnessed a 2.5 million year-over-year increase in customers.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Merck Expected to Witness Rise in Its Net Profit Margin in 2017

    For 2017, Merck & Co. (MRK) has projected its generally accepted accounting principles (or GAAP) earnings per share (or EPS) to fall in the range of $2.47–$2.62.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    OptumRx Continues to Boost UnitedHealth’s Pharmacy Care Services

    In its bid to control healthcare costs, UnitedHealth Group’s (UNH) OptumRx segment has been actively deploying data analytics across its Optum platform.

    By Margaret Patrick
  • uploads///careadvantage
    Company & Industry Overviews

    Inside the Latest Capability Advancement in Johnson & Johnson’s Orthopedics

    On January 9, JNJ’s Medical Device division announced its Orthopedic Episode of Care Approach, a data-driven program that will accelerate value-based care.

    By Sarah Collins
  • uploads///revenues
    Company & Industry Overviews

    Analyzing Zimmer Biomet Holdings’ Financial Guidance for 2016

    Zimmer Biomet revised its 2016 guidance after reporting its 3Q16 earnings. Its guidance for fiscal 2016 is estimated to be $7.63 billion–$7.65 billion.

    By Sarah Collins
  • uploads///STRATEGIC
    Company & Industry Overviews

    Baxter Advances Portfolio with Acquisition of Claris Injectables

    Through the acquisition of Claris Injectables, Baxter International aims to accelerate its strategy to become a leader in the global injectables market.

    By Sarah Collins
  • uploads///adverse events
    Company & Industry Overviews

    Alere’s Response to Abbott Laboratories’s Lawsuit to Terminate the Merger

    Alere (ALR) denied claims that any of the events that occurred during the last ten months would constitute any material change to the company’s value.

    By Sarah Collins
  • uploads///Profit GDP
    Company & Industry Overviews

    What’s Fueling the Bull Run? Richard Bernstein Explains

    A bull run with legs In Richard Bernstein Advisors’ October Insights newsletter, after dismissing the belief that the Federal Reserve is to blame for stock price inflation (IWD) (VTV), Richard Bernstein moved on to explain the reason for the current bull run. Stating that “fundamentals have improved dramatically, and have been a major support to the […]

    By David Ashworth
  • uploads///SEP Median Sep
    Macroeconomic Analysis

    September 2016 Projections: US GDP Growth and Unemployment

    FOMC (Federal Open Market Committee) participants have toned down their projections for US GDP growth in 2016 for the second successive quarter.

    By David Ashworth
  • uploads///small ticket big risk
    Financials

    US Student Debt: A $5,000 Debt Needs More Attention Than $100,000

    A small-ticket loan of $5,000 could be more harmful to the health of the US economy (SPY) (IWM) (QQQ) than a $100,000 loan.

    By Surbhi Jain
  • uploads///Trade Between Britain and the US
    Macroeconomic Analysis

    Has the Brexit Vote Derailed US Monetary Policy?

    After the policy meeting in June, Fed Chair Janet Yellen said that the Brexit vote could impact US monetary policy.

    By David Ashworth
  • uploads///bg pm
    Company & Industry Overviews

    Bunge Has Declared a Quarterly Dividend of $0.38 per Share

    Bunge (BG) has a market capitalization of $7.7 billion. BG rose by 0.56% to close at $50.0 per share as of March 1, 2016.

    By Gabriel Kane
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.